Prediction of the response to peg‐interferon‐alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment
- 25 May 2010
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 82 (7) , 1135-1142
Abstract
Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to develop a model, which improves the baseline prediction of response to PEG‐IFN for individual patients by including early HBV DNA measurements during treatment and to establish an early indication for cessation of treatment. One hundred thirty‐six patients treated with PEG‐IFN were included in the study. Response was defined as loss of HBeAg and HBV DNA 10 within 24 weeks was strongly associated with response when added to the baseline prediction model: OR 5.7 (95% CI: 1.70–20.0; P = 0.004). A dynamic model including HBV DNA decline during treatment provides more accurate predictions of response to PEG‐IFN. The model strongly supports individual decision making on treatment (dis)continuation in patients with HBeAg positive chronic hepatitis B. It is recommended that PEG‐IFN treatment is stopped by 24 weeks if HBV DNA declined 10. J. Med. Virol. 82: 1135–1142, 2010.Keywords
This publication has 21 references indexed in Scilit:
- EASL Clinical Practice Guidelines: Management of chronic hepatitis BJournal of Hepatology, 2009
- Modeling complex decay profiles of hepatitis B virus during antiviral therapy†‡Hepatology, 2008
- HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis BHepatology, 2008
- Relapse after treatment with peginterferon α-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis BGut, 2007
- Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment responseHepatology, 2006
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuationAlimentary Pharmacology & Therapeutics, 2005
- Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver DiseaseNew England Journal of Medicine, 2004
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004
- Methods for categorizing a prognostic variable in a multivariable settingStatistics in Medicine, 2003